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Clustered regularly interspaced short palindromic repeats (CRISPR)-
associated (Cas)9 genomic editing has revolutionized the generation
of mutant animals by simplifying the creation of null alleles in
virtually any organism. However, most current approaches with this
method require zygote injection, making it difficult to assess the
adult, tissue-specific functions of genes that are widely expressed
or which cause embryonic lethality when mutated. Here, we
describe the generation of cardiac-specific Cas9 transgenic mice,
which express high levels of Cas9 in the heart, but display no
overt defects. In proof-of-concept experiments, we used Adeno-
Associated Virus 9 (AAV9) to deliver single-guide RNA (sgRNA) that
targets the Myh6 locus exclusively in cardiomyocytes. Intraperito-
neal injection of postnatal cardiac-Cas9 transgenic mice with AAV9
encoding sgRNA against Myh6 resulted in robust editing of the
Myh6 locus. These mice displayed severe cardiomyopathy and loss
of cardiac function, with elevation of several markers of heart fail-
ure, confirming the effectiveness of this method of adult cardiac
gene deletion. Mice with cardiac-specific expression of Cas9 provide
a tool that will allow rapid and accurate deletion of genes following
a single injection of AAV9-sgRNAs, thereby circumventing embry-
onic lethality. This method will be useful for disease modeling and
provides a means of rapidly editing genes of interest in the heart.
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The ability to generate mice with either gain or loss-of-func-tion mutations has allowed the identification of genetic reg-
ulators of many aspects of development, physiology, and disease
(1). Historically, however, the generation of mutant mice has
been time-consuming and labor-intensive. The recent identifi-
cation of the clustered regularly interspaced short palindromic
repeats (CRISPR)-associated (Cas)9 system has revolutionized
the field of genetics and has greatly facilitated the generation of
genetically modified animals (2).
CRISPRs were first identified as part of the bacterial immune
system, playing a role in viral defense (3). The CRISPR-associ-
ated endonuclease Cas9 can be targeted to specific locations in
the genome via an RNA-guided system involving single-guide (sg)
RNAs to induce double-strand breaks in regions of interest (4–7).
The double-strand breaks induced by Cas9 cleavage are preferen-
tially repaired by Non-Homologous End Joining (NHEJ), an error-
prone form of DNA repair (8, 9). Consequently, short insertions or
deletions (indels) are frequently introduced at the site of Cas9
cleavage, leading to frameshift mutations and the induction of a
premature stop codon. Subsequently, translation of the protein of
interest is terminated, resulting in degradation of the transcript by
nonsense-mediated decay and protein loss (10, 11). As a result,
CRISPR/Cas9 has been increasingly used to generate loss-of-func-
tion mutations in genes of interest in a variety of organisms, including
zebrafish (12, 13), mice (14, 15), and nonhuman primates (16).
Despite the ease with which CRISPR/Cas9 can be used to
induce genetic mutations, most applications of the technology
have relied upon germline genomic editing in zygotes, rather
than in postnatal or adult animals. As a result, difficulties remain
with using the technology to analyze the function of genes that
cause embryonic lethality when mutated. Similarly, as many genes
are widely expressed in different tissues, most current applications
of CRISPR technology are less amenable to tissue-specific analysis
of genetic function.
Here, we describe the generation of transgenic mice that express
Cas9 exclusively in cardiomyocytes. In proof-of-concept experiments
using Adeno-Associated Virus to deliver single-guide RNA
(sgRNA) againstMyh6, we demonstrate robust cardiac-specific
genomic editing, termed cardioediting, at the Myh6 locus. En-
suing cardiac failure in these mice confirms the effectiveness of
this model for cardiac-specific genetic loss of function. These
cardiac Cas9-expressing animals will be useful for disease
modeling, cardiac gene editing, and exploring potential gene
therapies in the context of cardiac disease and dysfunction.
Results
Generation of Myh6-Cas9 Transgenic Mice. To perform cardiac-specific
genome editing with CRISPR/Cas9, we modified a construct
that expressed Cas9 from Streptococcus pyogenes, together with
a GFP tag, pSpCas9-2A-GFP (11), by replacing the CBh pro-
moter with the promoter for Myh6 (17), allowing expression of
Cas9 exclusively in cardiomyocytes. In addition, the 2A-GFP
fluorescent tag was replaced with a 2A-TdTomato construct,
allowing use of either GFP or TdTomato as a fluorescent reporter
for monitoring Cas9 expression (Fig. 1A). These constructs were
injected into mouse zygotes to generate transgenic Myh6-Cas9
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animals. We identified founder lines that robustly expressed Cas9 in
cardiomyocytes in both the Myh6-Cas9-2A-GFP (Fig. 1B) and
Myh6-Cas9-2A-TdTomato lines (Fig. 1C).
To confirm that Cas9 was correctly produced in these animals,
we examined expression of Cas9 by both real-time quantitative
PCR (RT-qPCR) (Fig. S1 A and B) and Western blot analysis for
Flag-tagged Cas9 (Fig. 1D). Cas9 was robustly expressed in the
heart, but was not detected in any other tissue examined by
qPCR (Fig. S1 A and B) consistent with the cardiac specificity of
the Myh6 promoter. In addition, we isolated cardiomyocytes and
examined expression of the Cas9 fluorescent reporter in these
cells. GFP or TdTomato was expressed in all cardiomyocytes,
suggesting robust expression of the transgene (Fig. S1 C and D).
Importantly, we have observed no overt defects in Cas9 trans-
genic animals, suggesting that high expression of Cas9 is not
harmful or toxic, consistent with previous reports (18).
AAV9-Driven Expression of sgRNA Against Myh6. To determine the
utility of this mouse model, we chose to use Adeno-Associated
Virus 9 (AAV9) to drive expression of an sgRNA against Myh6
(Fig. 1E). We identified and tested sgRNAs against exon 3 and
exon 8 ofMyh6, confirming in tissue culture using 10T1/2 cells that
they exhibited activity against the correct locus. These guides were
selected based on their specificity for the Myh6 locus, as well as
minimization of potential off-target sites (12 potential off-targets in
coding regions forMyh6 exon 3 sgRNA and 10 potential off-targets
in coding regions for Myh6 exon 8 sgRNA). Subsequently, the U6
promoter followed by the sgRNA against Myh6 and the guide
RNA scaffold were cloned into an AAV backbone (Fig. 2A). This
AAV vector also contained the CMV-promoter–driving expression
of the fluorescent protein ZsGreen, allowing monitoring of car-
diomyocyte transduction after AAV administration. The vector
plasmid was packaged into an AAV9 capsid serotype known to
efficiently transduce the heart upon systemic infusion (19).
Myh6 Expression Is Decreased After Knockdown via AAV in Cas9 Animals.
Animals were injected intraperitoneally with a single dose of 1 ×
1012 viral genomes of AAV9-Myh6 sgRNA targeting exon 3 or a
control injection of saline at postnatal day 10 (P10) (Fig. 2B). Five
weeks later, robust expression of ZsGreen in the hearts of these
animals was observed (Fig. 2C), with ∼75% of isolated car-
diomyocytes showing some degree of ZsGreen expression,
confirming that AAV was effectively transduced into the heart.
Consistent with effective transduction of AAV and knockdown of
Myh6, we observed extreme cardiac hypertrophy in animals that
were cardioedited (Fig. 2C). Histological analysis of Cas9+ ani-
mals with AAV-Myh6 sgRNA demonstrated extensive dilation of
both atria and ventricles, as well as thinning of the ventricle walls,
although minimal fibrosis was observed (Fig. 2D). Importantly, we
also injected AAV encoding sgRNA against luciferase and ob-
served no changes in heart morphology 12 wk after injection (Fig.
S2), confirming that the cardiac dilation observed after Myh6
knockdown was not a result of toxicity from AAV or an AAV/
sgRNA complex. Furthermore, hearts of control mice at 3 mo of
age, including Cas9+ alone, Cas9+ injected with AAV-luciferase
sgRNA, and injected with AAV-Myh6 sgRNA, showed similar
histology as WT mice, as seen by Masson’s trichrome stain, sug-
gesting that at this age none of these components alone contribute
to cardiac pathology. In contrast, knockdown of Myh6 via AAV-
Myh6 in a Cas9+ background resulted in fibrosis, indicative of the
cardiomyopathy observed in edited animals (Fig. S2).
Cardioediting of Myh6 Results in Cardiac Failure and Hypertrophy.
Consistent with the cardiac dilation noted (Fig. 2 C andD), we also
observed a marked reduction in fractional shortening in Myh6
edited animals, suggesting that loss of Myh6 severely impaired
cardiac performance (Fig. 3A). Similarly, by qPCR, we observed a
strong decrease in expression of Myh6 (Fig. 3B), concomitant with
an up-regulation of Myh7 expression (Fig. 3C), suggesting that
these animals had undergone compensatory myosin switching,
consistent with the presence of heart failure (20, 21). In addition,
natriuretic peptide A (Nppa) and natriuretic peptide B (Nppb),
sensitive markers of cardiac stress (22), were also up-regulated as
measured by qPCR, suggesting cardiac dysfunction (Fig. 3C).
Fig. 1. Generation of Myh6-Cas9 transgenic mice.
(A) Constructs encoding Myh6-Cas9-2A-GFP and Myh6-
Cas9-2A-TdTomato were generated and injected in
murine zygotes to generate transgenic mouse lines that
express Cas9 exclusively in cardiomyocytes. (B) Fluores-
cent microscopy confirms that GFP is robustly ex-
pressed in the heart of Myh6-Cas9-2A-GFP transgenic
animals. (Left) A negative littermate control. (C) Myh6-
Cas9-2A-TdTomato animals display strong ex-
pression of TdTomato in the heart by fluorescent
microscopy, whereas a negative littermate control
(Left) had no TdTomato expression. (D) Western blot
confirms that 3x-Flag–tagged Cas9 is correctly produced
in both Myh6-Cas9-2A-GFP and Myh6-Cas9-2A-
TdTomato lines. No band was observed in trans-
gene negative littermates, whereas GAPDH was
expressed. (E) Gene structure indicating that exon 3 and
exon 8 of murine Myh6 were targeted.








Isolation of cardiomyocytes from animals that were both Cas9+
and injected with AAV-Myh6 sgRNA revealed the presence of
cardiomyocytes that appeared both elongated and enlarged, in-
dicative of heart failure (Fig. 3D) (23). In addition, we noted cells
that were fragile, misshapen, bent, and floppy, lacking the char-
acteristic rod-like, striated appearance of adult cardiomyocytes,
suggesting that the lack of myosin perturbed cytoskeletal integrity.
Using genomic DNA obtained from isolated cardiomyocytes, we
observed robust editing at the Myh6 exon 3 locus using a T7 En-
donuclease I assay, used to assess genomic editing (Fig. S3A), in-
dicating the correct genomic location was targeted for cleavage
by Cas9.
Double-Guide Knockdown of Myh6. As use of a single guide limits
the types of indels that can be obtained in a target gene, we
sought to identify ways to increase the types of mutations we
could recover. We hypothesized that injecting virus that targeted
two separate exons might increase the types of mutations induced,
both by doubling the Myh6 loci that could be edited via induction
of indels and by allowing for either deletion or inversion of the
intervening fragment of genomic DNA found between the two
guide sites (24).
To test this theory, animals were intraperitoneal (i.p.)-injected
with a mixture of virus at P10 that contained sgRNAs against both
exon 3 and exon 8 of Myh6 (Fig. 1E). Within 3 wk of virus in-
jection, a strong reduction in fractional shortening was observed in
animals that were both Cas9+ and received dual AAV-Myh6
sgRNA (Fig. 4A). Similarly, by 4 wk postinjection, myosin
switching by qPCR (Fig. 4 B and C) and induction of Nppa and
Nppb (Fig. 4C) were observed. Furthermore, extensive cardiac
dilation and hypertrophy consistent with heart failure were evident
(Fig. 4D).
To confirm that both exons 3 and 8 ofMyh6 were targeted with
this strategy, T7 Endonuclease I assays were performed on iso-
lated cardiomyocytes. We observed editing at both the Myh6 exon
3 (Fig. S3B) and exon 8 (Fig. S3C) loci, consistent with the de-
livery of sgRNA targeting both genomic locations. Importantly,
using primers that flank the sgRNA sites of both exon 3 (Forward
Primer) and exon 8 (Reverse Primer), strong deletion of the in-
tervening genomic DNA was observed, as reflected in the smaller
∼800 base pair PCR product that is visible in edited animals (Fig.
S3D). Together, these data suggest that the delivery of sgRNA
targeting two locations could be used to increase the types of
mutations induced via CRISPR-mediated genomic editing.
Discussion
Here, we have generated a transgenic Cas9 system that enables
robust genomic editing exclusively in cardiomyocytes. Through
proof-of-concept experiments, we demonstrate that the knockdown
ofMyh6 quickly and efficiently induces massive cardiac dilation and
heart failure, within 3 wk of AAV delivery of sgRNA.We anticipate
that cardioediting can be extended to many other genes, enabling
the rapid assessment of gene functions in the heart. This system will
be an especially valuable tool for investigators interested in studying
the function of genes that cause embryonic lethality when mutated
or are expressed in a broad range of tissues. Although no overt
toxicity due to constitutive expression of Cas9 was observed, it re-
mains unclear if high levels of Cas9 could be problematic over long
periods of time, similar to the cardiotoxic effects reported with both
Cre (25) and GFP (26). However, the use of a tamoxifen-inducible
Myh6 promoter driving Cas9 expression could help alleviate this
potential problem by allowing for temporally controlled induction
of Cas9. Additionally, the use of newer versions of Cas9 that exhibit
strong reductions in off-target cleavage (27) will aid in increasing
the fidelity of Cas9-mediated gene knockdown, helping reduce the
likelihood of nonspecific genomic editing.
The double-sgRNA approach used here increases the number
of potential ways in which to disrupt the coding sequence of the
target gene. As a result, we suggest that simultaneous editing
with two guides that target proximal regions of the same gene
could enhance the knockdown of genes using postnatal delivery
of sgRNA by AAV9 in a Cas9+ transgenic animal. Furthermore,
the use of two guide RNAs enables the deletion of enhancers,
lncRNAs, or miRNA clusters, which are not as easily targeted
with the use of one sgRNA, thus expanding the types of genomic
editing that can be performed with this system.
The Cas9-mediated knockdown of Myh6 demonstrated here
confirms the essentiality of MYH6 in cardiac function and its role
in the development and progression of heart failure (28). Impor-
tantly, the phenotype observed following Myh6 knockdown is more
severe than that observed in adult mice that are heterozygous
Fig. 2. AAV9-driven expression of Myh6 sgRNA. (A) Myh6 sgRNA under
the control of the U6 promoter was cloned into an AAV9 backbone, to-
gether with a CMV-driven ZsGreen reporter. (B) Animals were injected
intraperitoneally at postnatal day 10 (P10) and subsequently analyzed 5–6 wk
later. (C) An example of a Myh6-Cas9-2A-TdTomato heart (red, Center)
that also received AAV-sgRNA againstMyh6 exon 3 (green, Right). Compared
with a littermate control animal, hearts from animals that received both Cas9
and sgRNA againstMyh6 displayed extreme cardiac dilation and hypertrophy.
(D) Histological section of a control heart and a heart that contained both
Cas9 and AAV-sgRNA against Myh6 exon 3. Edited hearts displayed thin-
ning of the ventricular walls and massive dilation of both the atria and
ventricles. Minimal fibrosis was observed by Masson’s trichrome staining.
(Scale bar, 40 μm.)
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for Myh6, which display modest adult onset heart failure (29),
suggesting that this approach leads to the loss of more than 50%
of Myh6. It is likely that the more severe phenotype is due to the
loss of both copies ofMyh6 in a fraction of myocytes as opposed to
the loss of one allele in all myocytes in the heterozygous Myh6
animals. Alternatively, it is possible that the enhanced phenotype
is due to the inability of the animal to adequately compensate for a
postnatal loss of myosin rather than a loss from early develop-
ment, as in the full-body heterozygous mice.
CRISPR/Cas9 has revolutionized the ease with which genomic
editing can be completed. Since mammalian CRISPR-based ge-
netic editing was first reported (6), the system has been used to
correct mutations in a variety of disease models, including Muscular
Dystrophy (30), Cystic Fibrosis (31), and Tyrosinemia (32). To-
gether, these studies are indicative of the broad application and uses
of the technology for genetic manipulation and correction. Future
uses of CRISPR are likely to involve attempted correction of dis-
eases in humans, after safety concerns are addressed (33, 34).
Despite the rapid progress that has been made in the CRISPR/
Cas9 field, challenges remain. One major limitation has been the
ability to deliver components of the CRISPR/Cas9 complex, par-
ticularly via AAV, due to the packaging limit of the virus (35). Here,
we circumvent this limitation by constitutively expressing Cas9 in
cardiomyocytes, allowing us to exclusively use AAV9 to deliver
sgRNA, which is well within the packaging limit of the virus. In
principle, cardioediting will enable rapid and efficient analysis of
Fig. 3. Cardioediting ofMyh6 results in cardiac failure.
(A) Echocardiography revealed a significant decrease in
fractional shortening of animals that were Cas9+ and
received AAV-sgRNA against Myh6 compared to litter-
mate controls. ***P < 0.001; n = 13 control animals, 11
edited animals. (B) qPCR revealed thatMyh6 expression
was significantly down-regulated following knockdown
of Myh6. ***P < 0.001; n = 5 control animals, 7 edited
animals. (C) Myh7, Nppa, and Nppb were significantly
up-regulated as detected by qPCR after Myh6 knock-
down. *P < 0.05, **P < 0.01; n = 5 control animals, 7
edited animals. (D) Isolated cardiomyocytes from a (i)
Myh6-Cas9-2A-TdTomato animal (top panel), (ii) wild-
type animal that received AAV-sgRNA only (second
panel), and (iii) Myh6-Cas9-2A-TdTomato positive ani-
mal that received AAV-sgRNA (bottom three panels).
Edited animals display cardiomyocyte elongation
characteristic of that seen in heart failure, as well as
cardiomyocytes that are bent and floppy, suggesting
loss of sarcomeric integrity and rigidity.








function of any coding gene in the heart by delivering a single dose
of AAV9 virus encoding an sgRNA against a gene of interest.
Materials and Methods
Generation of Transgenic Mice. All animal experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) of University of Texas
Southwestern Medical Center. Addgene plasmid #48138, pSpCas9(BB)-2A-
GFP (11), a gift from Feng Zhang, Massachusetts Institute of Technology, was
digested overnight with EcoRI to remove the 2A-GFP–coding region. The
digestion product was gel-purified using a Promega SV Gel and PCR Cleanup
System. The 2A-TdTomato construct was generated by cloning the T2A self-
cleaving peptide (EGRGSLLTCGDVEENPGP) upstream of the coding sequence
of the red fluorescent protein TdTomato. The 2A-TdTomato construct was
subsequently PCR-amplified and recombined in-frame with Cas9 in the PX458
vector using infusion cloning (Clontech), with the following primers:
F: 5′-AAAGAAAAAGGAATTCGCTAGCGAGGGCAGAGGA-3′
R: 5′-GCTCTAGTTAGAATTCATCGATTTACTTGTACAGCTC-3′.
To add the Myh6 promoter to both the Cas9-2A-GFP and -TdTomato re-
porter constructs, the plasmids were digested overnight with XbaI and AgeI
to remove the CBh promoter. The Myh6 promoter was amplified from the
BamHI to SalI sites using Phusion Taq Polymerase off the Myh6 PBS2-Sk+
vector (17). The Myh6 promoter was recombined into the digested PX458
vector using infusion cloning (Clontech) and the following primers:
F: 5′-GACAAATGGCTCTAGAGGATCCTGCAAGGTCACACA-3′
R: 5′-CCATGGTGGCACCGGTGTCGACTCAAACTCTTATGG-3′
All constructs were confirmed by sequencing. The Myh6-Cas9-2A-GFP con-
struct was digested from the backbone overnight with BamHI and NotI,
whereas the Myh6-Cas9-2A-TdTomato construct was digested overnight with
BamHI and NarI. Both digestion products were gel-purified before injection.
The transgenic constructs were injected in the pronucleus of murine embryos
followed by implantation in surrogate dams. Founder animals (F0) were
identified by tail biopsy followed by PCR for the presence of either GFP or
TdTomato and subsequently bred to wild-type animals.
Genotyping of Transgenic Mice. Transgenic mice were genotyped based on
the presence of either the GFP or TdTomato construct. Tail biopsies were
digested in 100 μL of 25-mM NaOH, 0.2-mM EDTA (pH 12) for 20 min at
95 °C. Tails were briefly centrifuged followed by addition of 100 μL of 40-mM
Tris·HCl (pH 5) and mixed to homogenize. Two microliters of this reaction was






sgRNA Identification and Cloning. Myh6 exon 3, Myh6 exon 8, and Luciferase
guide RNAs were identified using crispr.mit.edu. Guide sequences were
cloned into Addgene plasmid #42230 (6), a gift from Feng Zhang, using the
following primers:
Myh6 exon 3_F: 5′- CACCGTTAAGGCCAAGGTCGTGTCC -3′
Myh6 exon 3_R: 5′- AAACGGACACGACCTTGGCCTTAAC-3′
Myh6 exon 8_F: 5′- CACCGTATCCAGGCTAACCCCGCTC-3′
Myh6 exon 8_R: 5′- AAACGAGCGGGGTTAGCCTGGATAC-3′
Luciferase_F: 5′- CACCGTCCAGCGGATAGAATGGCGC-3′
Luciferase_R: 5′- AAACGCGCCATTCTATCCGCTGGAC-3′
Guide sequences were tested in culture using 10T1/2 cells before cloning
into the AAV backbone.
AAV Production and Delivery. Guide sequences and guide RNA scaffold were
digested using Nde I, which cut twice in the donor plasmid backbone, and
subcloned into the corresponding sites of pZac2.1-U6- CMV-ZsGreen (Uni-
versity of Pennsylvania) containing the AAV vector backbone or into the
pZac2.1-U6- CMV-ZsGreen backbone with the ZsGreen coding sequence
removed between the Sal1 sites.
Infectious recombinant AAV vector particles were generated in HEK293T
cells cultured in roller bottles by a cross-packaging approach whereby the
vector genome was packaged into AAV capsid serotype-9 (36). Viral stocks
were obtained by PEG precipitation and CsCl2 gradient centrifugation. Full
viral particles obtained from the gradient were extensively dialyzed in PBS
and stored in aliquots at −80 °C until use. The physical titer of recombinant
AAVs was determined by quantifying vector genomes (vg) packaged into
viral particles by real-time PCR against a standard curve of a plasmid con-
taining the vector genome (37). Values obtained were in the range of 5 ×
1012 to 5 × 1013 vg per milliliter.
Postnatal day 10 (P10) mice were administered 1 × 1012 viral genomes of
AAV (single-guide), diluted in 50 μL of saline. For double-guide injections, 5 ×
1011 viral genomes of each AAV guide were mixed, diluted in 50 μL of saline,
and delivered via i.p. injection at P10. Control animals received 50 μL of saline.
Quantitative Real-Time PCR. RNA was isolated from whole-heart tissue using
TRIzol (Invitrogen) according to manufacturer’s instructions. cDNA was
synthesized using BioRad iScript Reverse Transcription Supermix. qPCR was
performed using Applied Biosystems TaqMan probes forMyh6,Myh7, Nppa,
and Nppb and using Sybr Green for Cas9 (F Primer: 5′-GGACTCCCGGATGA-
ACACTA-3′; R Primer:5′-TCGCTTTCCAGCTTAGGGTA-3′). All reactions were
normalized using eukaryotic 18s rRNA endogenous control (Applied Biotech-
nologies). Experiments were performed on a StepOne Real-Time PCR System
(Life Technologies) and analyzed using the delta–delta Ct method.
Western Blot Analysis. Isolated hearts were snap-frozen in liquid nitrogen.
Lysates were generated by pulverizing cardiac tissue on ice in RIPA Buffer
(150 mM NaCl, 1% vol/vol Ipegal CA-630, 50 mM Tris-Cl pH 8.3, 0.5% wt/vol
sodium deoxycholate, 0.1% wt/vol SDS) together with additional protease
inhibitors (complete ULTRAmini tablet, Roche). BCA Protein Assay Kit (Pierce)
Fig. 4. Double-guide knockdown ofMyh6 results in cardiac failure and hypertrophy. (A) Animals that received AAV9-sgRNA against bothMyh6 exon 3 and exon 8
displayed a robust decrease in fractional shortening within 3 wk of AAV delivery. ***P < 0.001; n = 18 control animals, 13 edited animals. (B) Four weeks after AAV
delivery of dual sgRNAs, animals showed decreased expression ofMyh6 by qPCR. *P < 0.05; n = 7 control animals, 6 edited animals. (C) AfterMyh6 knockdown with
two AAV-sgRNAs, animals showed elevated levels ofMyh7, Nppa, and Nppb by qPCR within 4 wk of AAV delivery. *P < 0.05, **P < 0.01, ***P < 0.001; n = 7 control
animals, 6 edited animals. (D) Animals that were Cas9+ and received dual AAV-sgRNA against Myh6 exhibited cardiac dilation within 4 wk of AAV delivery.
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was used to determine protein concentrations. Lysates were separated using
any kD Mini-Protean TGX precast gels (BioRad). Samples were transferred
onto Immobilon P membranes (Millipore) and blocked for 1 h at room tem-
perature in 5% (wt/vol) nonfat dry milk in Tris-buffered saline with Tween 20
(TBST). Primary antibodies were hybridized overnight at 4 °C [GAPDH (Millipore),
1:1,000 dilution; Flag-HRP–conjugated (Sigma), 1:1,000 dilution]. Membranes
were washed three times for 5 min each in TBST. Blots for GAPDH were in-
cubated with HRP-conjugated secondary antibody (BioRad) at a 1:20,000 dilution
for 1 h at room temperature. Chemiluminescent substrate was used to develop
blots, which were then exposed to audioradiographic film.
Echocardiography. Cardiac function was determined by echocardiography on
conscious animals at either 3 wk post-AAV delivery (double-guide animals) or
5–6 wk post-AAV delivery (single-guide animals). This analysis was per-
formed using a Visual SonicsVevo 2100 system equipped with a 35-MHz
transducer. Fractional shortening (FS) of the left ventricle was determined
using Left Ventricle Internal Dimension at Diastole (LVIDd) and Left Ventricle
Internal Dimension at Systole (LVIDs). FS was calculated according to the
formula FS(%)= [(LVIDd − LVIDs)/LVIDd] × 100.
Cardiomyocyte Isolation. Cardiomyocytes were isolated from adult animals as
previously described (38, 39). Animals were initially anesthetized with 3%
isoflurane and subsequently maintained with 1% isoflurane. Hearts were
removed from the animals. Aortic cannulation was performed using a
Langendorff Apparatus with constant flow. Cardiac digestion was achieved
by perfusion with a Tyrode’s solution consisting of 0.2 mg/mL Liberase DH
(Roche), 0.14 mg/mL Trypsin (Gibco/Invitrogen), 0.02 mM CaCl2, 10 mM
glucose, 5 mM Hepes, 5.4 mM KCl, 1.2 mM MgCl2, 150 mM NaCl, and 2 mM
sodium pyruvate (pH 7.4). Subsequent to tissue softening, the heart was
isolated and delicately minced, filtered, and equilibrated at room temper-
ature using Tyrode’s solution also containing 200 μM CaCl2 and 1% BSA.
Histological Analysis. Hearts were isolated and fixed in 4% paraformaldehyde
in PBS for 48 h at 4 °C followed by paraffin embedding and sectioning.
Masson’s trichrome stain was performed according to standard protocols.
T7 Endonuclease Assay.Genomic DNAwas isolated from either whole-heart or
isolated cardiomyocytes using a DNeasy Blood and Tissue Kit (Qiagen). Exons
were PCR-amplified using Taq Polymerase (New England Biolabs) and the
following primers:
Myh6 exon 3 F Primer: 5′-AGGCACCCTTACCCCACATA-3′
Myh6 exon 3 R Primer: 5′-CAACCCCTTTCCCTAAGCCG-3′
Myh6 exon 8 F Primer: 5′-GGTCGGTGCAGACAATCTTT-3′
Myh6 exon 8 R Primer: 5′-CCATTTTCTTGACACATTTGAGG-3′
PCR products were hybridized and subsequently digested with T7 Endo-
nuclease I for 30 min at 37 °C. Digestion products were separated using
standard agarose gels (1.5%).
To detect deletion of the genomic DNA between the exon 3 and exon 8
guide sites, the following primers were used:
F: 5′-AGGCACCCTTACCCCACATA-3′
R: 5′-GGGAAAACAGCTACCAGGCT-3′
Statistical Analysis. For all experiments, pooled data consist of studies using both
Myh6-Cas9-2A-GFP and Myh6-Cas9-2A-TdTomato animals. Controls represent a
compilation of data from animals that were (i) wild type and received a saline
injection, (ii) wild type and received injection of AAV, and (iii) Cas9+ and re-
ceived a saline injection. All qPCR statistics are displayed as mean ± SEM while
echocardiograms are displayed as mean ± SD. An unpaired t test with Welch’s
correction was used to determine statistical significance. Any result with a
P value <0.05 was considered statistically significant.
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